The Elliot's Neurological Specialties clinic combines medical treatments to slow MS progression with holistic approaches to ...

Scientists say they are on the brink of creating a breakthrough treatment for multiple sclerosis which could repair nerve damage caused by the condition. MS causes the body to attack myelin, the ...

AB Science has secured a patent in Japan, valid through February 2041, covering the use of masitinib for progressive forms of MS.

ZURICH (Reuters) - Swiss drugmaker Roche Holding said a mid-phase study found its ocrelizumab drug maintained significant reduction in disease activity for multiple sclerosis patients for almost two ...

A brain protein called ANO2 has emerged as a new piece of the puzzle linking Epstein-Barr virus (EBV) infections and MS ...

FRANKFURT (Reuters) -Swiss drugmaker Roche said on Monday that a late-stage trial testing ‌its multiple sclerosis drug candidate fenebrutinib against the relapsing form ‌of the disease achieved its ...

Women are less likely than men to receive drugs for multiple sclerosis (MS) between the ages of 18 to 40, during women's childbearing years, even when those drugs have been shown to be safe for use ...

Tolebrutinib delayed disability progression by 31% in people with secondary progressive multiple sclerosis No drugs are currently approved to treat this type of MS WEDNESDAY, April 9, 2025 (HealthDay ...

The amount of money people pay out-of-pocket for branded drugs to treat neurological diseases like multiple sclerosis (MS), Alzheimer's, and Parkinson's disease continues to rise, especially for MS ...

Even women with more severe MS cases are less likely than men to get critical treatments, a new study finds. Women under age 40 with multiple sclerosis are 8 percent less likely than men to receive ...

MINNEAPOLIS — Women are less likely than men to receive drugs for multiple sclerosis (MS) between the ages of 18 to 40, during women’s childbearing years, even when those drugs have been shown to be ...